

# Electronic Supplementary Material

## A highly selective fluorescent probe for real-time imaging of

## UDP-glucuronosyltransferase 1A8 in living cells and tissues

Mingyue Zhu <sup>\*1,2</sup>, Zhenhao Tian <sup>\*3</sup>, Lingling Jin<sup>2</sup>, Xiaokui Huo<sup>2</sup>, Chao Wang<sup>2</sup>, Jingnan Cui<sup>4</sup>, Yan Tian (✉)<sup>2</sup>, Xiangge Tian (✉)<sup>2</sup>, Lei Feng (✉)<sup>1,2</sup>

1 College of Pharmacy, School of Medicine, Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Hangzhou Normal University, Hangzhou 311121, China

2 Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, College of Pharmacy, College of Integrative Medicine, Dalian Medical University, Dalian 116044, China

3 School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China


4 State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China

E-mails: [leifeng@dmu.edu.cn](mailto:leifeng@dmu.edu.cn) (Feng L); [tianxiangge1990@163.com](mailto:tianxiangge1990@163.com) (Tian X); [tiany2004@126.com](mailto:tiany2004@126.com) (Tian Y)


## Table of content

<b>1.1 Synthetic procedures</b> .....	1
<b>Scheme S1</b> The synthesis pathway of <b>BDMP</b> . .....	1
<b>1.2 NMR spectra and HRMS data</b> .....	1


<b>Fig. S1.</b> $^1\text{H}$ NMR spectrum of compound <b>1</b> in $\text{CDCl}_3$ . .....	1
<b>Fig. S2.</b> $^1\text{H}$ NMR spectrum of <b>BDMP</b> in $\text{DMSO-}d_6$ . .....	2
<b>Fig. S3.</b> $^{13}\text{C}$ NMR spectrum of <b>BDMP</b> in $\text{DMSO-}d_6$ . .....	2
<b>Fig. S4.</b> HRMS of <b>BDMP</b> . .....	3
<b>Fig. S5.</b> HRMS of the glucuronidation product of <b>BDMP</b> .....	3
<b>1.3 Supplementary Figures</b> .....	3
<b>Fig. S6.</b> The Cytotoxicity of <b>BDMP</b> toward LoVo and HCT-15 cells, respectively. ....	3
<b>Fig. S7.</b> The fluorescence imaging of UGT1A8 in LoVo cells .....	3




**Scheme S1** The synthesis pathway of **BDMP**.




**Fig. S1.**  $^1\text{H}$  NMR spectrum of compound **1** in  $\text{CDCl}_3$ .




**Fig. S2.**  $^1\text{H}$  NMR spectrum of **BDMP** in  $\text{DMSO-}d_6$ .




**Fig. S3.**  $^{13}\text{C}$  NMR spectrum of **BDMP** in  $\text{DMSO-}d_6$ .




**Fig. S4.** HRMS of **BDMP**.



**Fig. S5.** HRMS of the glucuronidation product of **BDMP**.



**Fig. S6** The Cytotoxicity of **BDMP** toward LoVo (A) and HCT-15 (B) cells, respectively.



**Fig. S7** (a, e, i) The fluorescence field of LoVo cells; (b, f, j) the staining of nucleus by Hoechst 33342; (c, g, k) the bright field for the LoVo cells; (d, h, l) the merge field

of the confocal fluorescence images. The scale bar is 50  $\mu\text{m}$ . **BDMP**:  $\lambda_{\text{ex}}$  514 nm;  $\lambda_{\text{em}}$  550-610 nm.